Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients
Abstract Background Interleukin-2 (IL-2) is an important immunotherapy cytokine for various diseases including cancer. Some studies reported the efficacy and safety on cisplatin combined with IL-2 versus cisplatin alone for treating malignant pleural effusion (MPE) through thoracic injection. Method...
Main Authors: | Liping Han, Qiufang Jiang, Wei Yao, Tian Fu, Qingdi Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4581-5 |
Similar Items
-
Approach to malignant pleural effusions: Role of pleural manometry exemplified by case scenarios
by: Irfan Ismail Ayub
Published: (2019-01-01) -
Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
by: Eiji Takeuchi, et al.
Published: (2020-10-01) -
Diagnostic role of interleukin -33 in the differentiation of pleural effusions especially tuberculous and malignant effusions
by: Abdel-sadek Hamed Al-aarag, et al.
Published: (2019-06-01) -
Immune Regulation of Interleukin-27 in Malignant Pleural Effusion
by: Shi Li, et al.
Published: (2015-01-01) -
Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions
by: Maoshui Wang, et al.
Published: (2014-01-01)